Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for central nervous system (CNS) disorders, today
announced its financial results for the first quarter ended March
31, 2021 and provided a corporate update.
“The acceptance of our sNDAs by the FDA is an important step
towards a potential new treatment option for patients living with
bipolar depression, a condition with a limited number of approved
treatments. While preparing for this significant opportunity, our
team will continue to execute on our commercial objectives for
CAPLYTA and advance our robust pipeline,” said Dr. Sharon Mates,
Chairman and CEO of Intra-Cellular Therapies.
First Quarter Financial Highlights:
- Total revenues were $15.9 million
for the first quarter of 2021, compared to $1.1 million of total
revenues for the first quarter of 2020. Net product revenues of
CAPLYTA were $15.6 million for the first quarter of 2021, compared
to $0.9 million in net product revenues of CAPLYTA for the same
period in 2020.
- Cost of product sales were $1.5
million in the first quarter of 2021 compared to $0.1 million for
the first quarter of 2020.
- Research and development (R&D)
expenses for the first quarter of 2021 were $15.1 million,
compared to $16.0 million for the first quarter of 2020.
This decrease is due primarily to a decrease in manufacturing
expense and is partially offset by an increase of lumateperone
clinical and non-clinical expenses.
- Selling, general and administrative
(SG&A) expenses were $52.6 million for the first quarter of
2021, compared to $34.1 million for the same period in 2020. This
increase is primarily due to an increase in sales related labor
costs and commercialization costs.
- Net loss for the quarter ended
March 31, 2021 was $52.7 million compared to a net loss of $47.4
million for the quarter ended March 31, 2020.
- Cash, cash equivalents, restricted
cash and investment securities totaled $613.4 million at March 31,
2021, compared to $658.8 million at December 31, 2020.
COMMERCIAL HIGHLIGHTS
- Despite the continued impact of
COVID-19 on the healthcare system during the first quarter, our
commercial organization continued to effectively engage with our
prescribing audience through a hybrid model of in-person and
virtual interactions, enhanced by digital marketing
initiatives.
- First quarter CAPLYTA results
reflect strong commercial execution delivering continued
prescription growth, increasing total prescriptions 23% versus the
fourth quarter.
- CAPLYTA market access coverage is
strong with greater than 95% of covered lives in both Medicare Part
D and State Medicaid, the major payer channels in schizophrenia.
Our LytaLink program continues to be highly competitive and
effective in supporting prescribing physicians and eligible
patients’ access to CAPLYTA.
CLINICAL HIGHLIGHTS
Lumateperone - Bipolar Depression Program:
- The U.S. Food and Drug
Administration (FDA) has accepted for review the sNDAs for
lumateperone for the treatment of depressive episodes associated
with bipolar I or II disorder (bipolar depression) as monotherapy
and as adjunctive therapy with lithium or valproate. The FDA has
assigned a PDUFA target action date of December 17, 2021 for these
applications.
- At the American Psychiatric
Association (APA) Annual Meeting held from May 1-3, 2021, we
had several presentations describing lumateperone study results.
These included results from Study ‘402, a global Phase 3 clinical
trial evaluating lumateperone as adjunctive therapy to lithium or
valproate in the treatment of major depressive episodes associated
with bipolar I or bipolar II disorder and analyses from Study ‘404
highlighting the efficacy results of patients with bipolar
depression who exhibit mixed features. Another presentation
summarized the overall safety and tolerability profile of the
bipolar depression monotherapy program.
Other Lumateperone Programs
- Mixed Features program: Study ‘403
evaluating lumateperone 42 mg in patients with major depressive
disorder (MDD) and in patients with bipolar depression who exhibit
mixed features is ongoing.
- Adjunctive MDD program: Clinical
conduct in two studies, Studies ‘501 and ‘502, our Phase 3 clinical
trials evaluating lumateperone 42 mg as an adjunctive therapy to
antidepressants for the treatment of MDD is anticipated to begin
later this year.
- Lumateperone Long Acting Injectable
(LLAI) formulation: Study ITI-007-025, a Phase 1 single ascending
dose study of LLAI, a formulation designed to be administered
subcutaneously and to maintain therapeutic levels of lumateperone
for at least one month is ongoing. Initial results from this study
are anticipated in the second half of 2021.
CAPLYTA- Schizophrenia
- Announced the publication of “Safety
and tolerability of lumateperone 42 mg: An open-label antipsychotic
switch study in outpatients with stable schizophrenia” (Correll et
al. 2021) in the journal, Schizophrenia Research.
- At APA we presented analyses from
Study 303, our long-term safety schizophrenia study, evaluating the
antidepressant effects of CAPLYTA in patients with schizophrenia
with co-morbid depression, with and without concomitant
antidepressant treatments.
Other Programs
- ITI-1284 program: We introduced
ITI-1284 ODT-SL, a deuterated form of lumateperone, a new molecular
entity formulated as an orally disintegrating tablet for sublingual
administration. We plan to initiate studies evaluating ITI-1284
ODT-SL for the treatment of behavioral disturbances in patients
with dementia, the treatment of dementia-related psychosis and the
treatment of certain depressive disorders in the elderly.
- Phosphodiesterase type I inhibitor (PDE1) program: Our PDE1
inhibitor program is focused on diseases in which the PDE1 enzyme
is over-expressed and/or abnormal immune cell function contributes
to disease pathology. This suggests therapeutic potential across a
variety of diseases, including neurological and cardiovascular
diseases, as well as cancer.
- We plan to advance
our lead molecule, lenrispodun (ITI-214), into a Phase 2 clinical
study in Parkinson’s disease in the second half of 2021.
- At the American Association for Cancer
Research (AACR) Virtual Annual Meeting, we presented preclinical
data supporting the potential of PDE1 inhibition to enhance the
anti-tumor effects of immunotherapies by altering the tumor
micro-environment. Our prior studies elucidating the
neuroprotective and anti-inflammatory effects of PDE1 inhibitors in
the brain by regulating microglia function (brain resident
macrophage-like cells) led to our exploration of similar effects
outside the brain. Therefore, we hypothesized PDE1 inhibition could
result in antitumor effects by controlling similar functions of
macrophages in the tumor micro-environment. Our experiments
indicate PDE1 inhibition prevents the migration and accumulation of
monocytes and macrophages in the tumor micro-environment and could
represent a novel and broadly applicable approach to the treatment
of immune responsive cancers.
- ITI-333 program in opioid use
disorder: Study ITI-333-001, a Phase 1 single ascending dose study
evaluating the safety, tolerability and pharmacokinetics of ITI-333
in healthy volunteers is ongoing. Results from this study are
anticipated in the second half of 2021.
Conference Call and Webcast Details
The Company will host a live conference call and webcast today
at 8:30 AM Eastern Time to discuss the Company’s
financial results and provide a corporate update. The live webcast
and subsequent replay may be accessed by visiting the Company’s
website at www.intracellulartherapies.com. Please connect to
the Company’s website at least 5-10 minutes prior to the live
webcast to ensure adequate time for any necessary software
download. Alternatively, please call 1-(844) 835-6563 (U.S.) or
1-(970) 315-3916 (international) to listen to the live conference
call. The conference ID number for the live call is 3244409. Please
dial in approximately 10 minutes prior to the call.
CAPLYTA® (lumateperone) is indicated for the treatment of
schizophrenia in adults. CAPLYTA is available in 42 mg
capsules.
Important Safety Information
Boxed Warning: Elderly patients with dementia-related
psychosis treated with antipsychotic drugs are at an increased risk
of death. CAPLYTA is not approved for the treatment of patients
with dementia-related psychosis.
Contraindications: CAPLYTA is contraindicated
in patients with known hypersensitivity to lumateperone or any
components of CAPLYTA. Reactions have included pruritus, rash (e.g.
allergic dermatitis, papular rash, and generalized rash), and
urticaria.
Warnings & Precautions: Antipsychotic drugs
have been reported to cause:
- Cerebrovascular Adverse Reactions in Elderly Patients
with Dementia-Related Psychosis, including stroke and
transient ischemic attack. See Boxed Warning above.
- Neuroleptic Malignant Syndrome (NMS), which is
a potentially fatal reaction. Signs and symptoms include: high
fever, stiff muscles, confusion, changes in breathing, heart rate,
and blood pressure, elevated creatinine phosphokinase,
myoglobinuria (and/or rhabdomyolysis), and acute renal failure.
Patients who experience signs and symptoms of NMS should
immediately contact their doctor or go to the emergency room.
- Tardive Dyskinesia, a syndrome of uncontrolled
body movements in the face, tongue, or other body parts, which may
increase with duration of treatment and total cumulative dose. TD
may not go away, even if CAPLYTA is discontinued. It can also occur
after CAPLYTA is discontinued.
- Metabolic Changes, including hyperglycemia,
diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in
some cases extreme and associated with ketoacidosis, hyperosmolar
coma or death, has been reported in patients treated with
antipsychotics. Measure weight and assess fasting plasma glucose
and lipids when initiating CAPLYTA and monitor periodically during
long-term treatment.
- Leukopenia, Neutropenia, and Agranulocytosis (including
fatal cases). Complete blood counts should be performed in
patients with pre-existing low white blood cell count (WBC) or
history of leukopenia or neutropenia. CAPLYTA should be
discontinued if clinically significant decline in WBC occurs in
absence of other causative factors.
- Decreased Blood Pressure & Dizziness.
Patients may feel lightheaded, dizzy or faint when they rise too
quickly from a sitting or lying position (orthostatic hypotension).
Heart rate and blood pressure should be monitored and patients
should be warned with known cardiovascular or cerebrovascular
disease. Orthostatic vital signs should be monitored in patients
who are vulnerable to hypotension.
- Falls. CAPLYTA may cause sleepiness or
dizziness and can slow thinking and motor skills, which may lead to
falls and, consequently, fractures and other injuries. Patients
should be assessed for risk when using CAPLYTA.
- Seizures. CAPLYTA should be used cautiously in
patients with a history of seizures or with conditions that lower
seizure threshold.
- Sleepiness and Trouble Concentrating. Patients
should use caution when operating machinery or motor vehicles until
they know how CAPLYTA affects them.
- Body Temperature Dysregulation. CAPLYTA should
be used with caution in patients who may experience conditions that
may increase core body temperature such as strenuous exercise,
extreme heat, dehydration, or concomitant anticholinergics.
- Dysphagia. CAPLYTA should be used with caution
in patients at risk for aspiration.
Drug Interactions: CAPLYTA should not be used
with CYP3A4 inducers, moderate or strong CYP3A4 inhibitors and UGT
inhibitors.
Special Populations: Newborn infants exposed to
antipsychotic drugs during the third trimester of pregnancy are at
risk for extrapyramidal and/or withdrawal symptoms following
delivery. Breastfeeding is not recommended. Use of CAPLYTA should
be avoided in patients with moderate or severe liver problems.
Adverse Reactions: The most common adverse
reactions in clinical trials with CAPLYTA vs. placebo were
somnolence/sedation (24% vs. 10%) and dry mouth (6% vs. 2%).
Please click here to see full Prescribing Information
including Boxed Warning.
About CAPLYTA (lumateperone)
CAPLYTA 42mg/day is an oral, once daily atypical antipsychotic
approved for the treatment of schizophrenia of adults. While the
mechanism of action of CAPLYTA in the treatment of schizophrenia is
unknown, the efficacy of CAPLYTA could be mediated through a
combination of antagonist activity at central serotonin 5-HT2A
receptors and postsynaptic antagonist activity at central dopamine
D2 receptors.
Lumateperone is being investigated for the treatment of bipolar
depression, depression and other neuropsychiatric and neurological
disorders. CAPLYTA is not FDA approved for these disorders.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company
founded on Nobel prize-winning research that allows us to
understand how therapies affect the inner-workings of cells in the
body. The company leverages this intracellular approach to develop
innovative treatments for people living with complex psychiatric
and neurologic diseases. For more information, please
visit www.intracellulartherapies.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, our expectations regarding the
commercialization of CAPLYTA; our expectations regarding the sNDAs,
including the adequacy of the data contained in the sNDAs to serve
as the basis for approval of lumateperone for the treatment of
depressive episodes associated with bipolar I or II disorder both
as monotherapy and as adjunctive therapy in adults; the potential
approval by the FDA of the sNDAs for lumateperone for the treatment
of bipolar depression; the potential timing of review and action by
the FDA with respect to the sNDAs; our plans and expected timing to
initiate our lumateperone clinical studies in major depressive
disorder; our plans and expected timing for results from our
lumateperone long-acting injectable clinical trial; our plans and
expected timing for results from our ITI-333 clinical trial; our
development plans for our PDE program, including ITI-214, and the
potential benefits of PDE1 inhibition; our development plans for
our ITI-1284 program; our beliefs about the potential utility of
our product candidates; and development efforts and plans under the
caption “About Intra-Cellular Therapies.” All such forward-looking
statements are based on management's present expectations and are
subject to certain factors, risks and uncertainties that may cause
actual results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, but are not limited to, the
following: whether the preclinical and clinical results of the
lumateperone studies will meet the regulatory requirements for
approval by the FDA for the proposed indications; whether
the sNDAs will be approved by the FDA and whether the FDA will
complete its review within its target timelines, including its
target action date; whether the FDA will require additional
information, whether we will be able to provide in a timely manner
any additional information that the FDA requests, and whether such
additional information will be satisfactory to the FDA; there are
no guarantees that CAPLYTA will be commercially successful; we may
encounter issues, delays or other challenges in commercializing
CAPLYTA; the COVID-19 pandemic may negatively impact our commercial
plans and sales for CAPLYTA; the COVID-19 pandemic may negatively
impact the conduct of, and the timing of enrollment, completion and
reporting with respect to, our clinical trials; whether CAPLYTA
receives adequate reimbursement from third-party payors; the degree
to which CAPLYTA receives acceptance from patients and physicians
for its approved indication; challenges associated with execution
of our sales activities, which in each case could limit the
potential of our product; results achieved in CAPLYTA in the
treatment of schizophrenia following commercial launch of the
product may be different than observed in clinical trials, and may
vary among patients; any other impacts on our business as a result
of or related to the COVID-19 pandemic; risks associated with our
current and planned clinical trials; we may encounter unexpected
safety or tolerability issues with CAPLYTA following commercial
launch for the treatment of schizophrenia or in ongoing or future
trials and other development activities; our other product
candidates may not be successful or may take longer and be more
costly than anticipated; product candidates that appeared promising
in earlier research and clinical trials may not demonstrate safety
and/or efficacy in larger-scale or later clinical trials or in
clinical trials for other indications; our proposals with respect
to the regulatory path for our product candidates may not be
acceptable to the FDA; our reliance on collaborative partners and
other third parties for development of our product candidates; and
the other risk factors detailed in our public filings with
the Securities and Exchange Commission. All statements
contained in this press release are made only as of the date of
this press release, and we do not intend to update this information
unless required by law.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President,
Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc.Lisa
Burnscradinovic@burnsmc.com212-213-0006
MEDIA INQUIRIES:
Ana FullmerCorporate Media Relations
W2Owcgafullmer@wcgworld.com202-507-0130
INTRA-CELLULAR THERAPIES,
INC.CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
|
Three Months Ended March 31, |
|
|
2021 |
|
|
2020 |
|
Revenues |
|
|
Product sales, net |
$ |
15,578,905 |
|
$ |
882,516 |
|
Grant revenue |
|
299,424 |
|
|
200,963 |
|
Total revenues |
|
15,878,329 |
|
|
1,083,479 |
|
|
|
|
Operating expenses: |
|
|
Cost of product sales |
|
1,455,215 |
|
|
69,311 |
|
Research and development |
|
15,058,168 |
|
|
16,003,326 |
|
Selling, general and administrative |
|
52,583,639 |
|
|
34,096,366 |
|
|
|
|
Total operating expenses |
|
69,097,022 |
|
|
50,169,003 |
|
|
|
|
Loss from operations |
|
(53,218,693 |
) |
|
(49,085,524 |
) |
Interest income |
|
483,750 |
|
|
1,678,203 |
|
|
|
|
Loss before provision for income taxes |
|
(52,734,943 |
) |
|
(47,407,321 |
) |
Income tax expense |
|
5,000 |
|
|
3,281 |
|
Net loss |
$ |
(52,739,943 |
) |
$ |
(47,410,602 |
) |
|
|
|
Net loss per common share: |
|
|
Basic & Diluted |
$ |
(0.65 |
) |
$ |
(0.73 |
) |
Weighted average number of common shares: |
|
|
Basic & Diluted |
|
80,946,450 |
|
|
65,106,103 |
|
(1) The condensed consolidated statements of
operations for the quarters ended March 31, 2021 and 2020 have been
derived from the financial statements but do not include all of the
information and footnotes required by accounting principles
generally accepted in the United States for complete financial
statements.
INTRA-CELLULAR THERAPIES,
INC.CONDENSED CONSOLIDATED BALANCE
SHEETS
|
|
|
|
March 31,2021 |
December 31,2020 |
|
(Unaudited) |
|
Assets |
|
|
Current assets: |
|
|
Cash and cash equivalents |
$ |
129,979,888 |
|
$ |
60,045,933 |
|
Investment securities, available-for-sale |
|
481,984,786 |
|
|
597,402,126 |
|
Restricted cash |
|
1,400,000 |
|
|
1,400,000 |
|
Accounts receivable, net less allowance of $120,000 at March 31,
2021 and December 31, 2020 |
|
13,661,992 |
|
|
10,764,583 |
|
Inventory |
|
7,579,393 |
|
|
7,056,385 |
|
Prepaid expenses and other current assets |
|
14,494,384 |
|
|
14,235,455 |
|
|
|
|
Total current assets |
|
649,100,443 |
|
|
690,904,482 |
|
Property and equipment, net |
|
1,871,338 |
|
|
1,998,346 |
|
Right of use assets, net |
|
23,430,703 |
|
|
24,324,762 |
|
Other assets |
|
86,084 |
|
|
86,084 |
|
|
|
|
Total assets |
$ |
674,488,568 |
|
$ |
717,313,674 |
|
|
|
|
Liabilities and stockholders’ equity |
|
|
Current liabilities: |
|
|
Accounts payable |
$ |
8,720,957 |
|
$ |
5,501,825 |
|
Accrued and other current liabilities |
|
13,491,620 |
|
|
10,902,117 |
|
Lease liabilities, short-term |
|
5,573,240 |
|
|
5,541,802 |
|
Accrued employee benefits |
|
11,915,893 |
|
|
14,907,479 |
|
|
|
|
Total current liabilities |
|
39,701,710 |
|
|
36,853,223 |
|
Lease liabilities |
|
22,637,100 |
|
|
23,600,347 |
|
|
|
|
Total liabilities |
|
62,338,810 |
|
|
60,453,570 |
|
Stockholders’ equity: |
|
|
Common stock, $0.0001 par value: 100,000,000 shares authorized;
81,133,849 and 80,142,797 shares issued and outstanding at March
31, 2021 and December 31, 2020, respectively |
|
8,113 |
|
|
8,046 |
|
Additional paid-in capital |
|
1,601,739,075 |
|
|
1,593,475,506 |
|
Accumulated deficit |
|
(989,843,975 |
) |
|
(937,104,032 |
) |
Accumulated comprehensive income |
|
246,545 |
|
|
480,584 |
|
|
|
|
Total stockholders’ equity |
|
612,149,758 |
|
|
656,860,104 |
|
|
|
|
Total liabilities and stockholders’ equity |
$ |
674,488,568 |
|
$ |
717,313,674 |
|
|
|
|
(1) The condensed consolidated balance sheets
at March 31, 2021 and December 31, 2020 have been derived from the
financial statements but do not include all of the information and
footnotes required by accounting principles generally accepted
in the United States for complete financial
statements.
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024